Bionova Scientific’s Post

I’m excited to reconnect with familiar faces and meet new ones at Meeting on the Mesa. If you're engaged in early-stage vector production development, Phase I, or commercialization, let's explore innovative solutions for vector production and purification. Starting right is key to lowering costs for new modality drugs. #MeetingOnTheMesa #Innovation #Biotech #DrugDevelopment

🔬✨ In this week's #TechTales post, we talk about the versatility of our MOFs in encapsulating and transporting various types of cargo for targeted drug delivery. At Vector Bioscience Cambridge, we customise our #NanoShuttles to optimise the encapsulation of any treatment, molecule, or combination of them. Our platform technology is cargo-agnostic, allowing for more precise and localised drug delivery and controlled drug release. This adaptability is crucial as it allows for the development of tailored therapies enhancing treatment effectiveness and patient outcomes. Stay tuned for our next #TechTales posts as we continue to explore the science driving our breakthroughs. 🚀🔗 #DrugDelivery #Nanotechnology #Biopharma #Biotech #Innovation #MOFs #CancerTreatment

Exciting times in biotech! The first half of 2024 has seen near-record investment levels. Check out the EY German Biotechnology Report 2024 to see how we're part of this thriving sector.

Exciting times in biotech! The first half of 2024 has seen near-record investment levels. Check out the EY German Biotechnology Report 2024 to see how we're part of this thriving sector.

Exciting times in biotech! The first half of 2024 has seen near-record investment levels. Check out the EY German Biotechnology Report 2024 to see how we're part of this thriving sector.

Navigating the funding landscape can be tricky for biotech companies at all stages, from initial research and clinical trials to scaling up capabilities. Our recent roundtable discussions with over 90 Biotech CEOs, held in partnership with AusBiotech, shed light on the challenges and opportunities shaping the industry. Discover how to navigate the complexities of funding and innovation in the biotech sector in our latest article: https://okt.to/ugJm1o #Biotech #LifeSciences

Exciting insights from our recent roundtables, hosted in partnership with @AusBiotech. We were joined by more than 90 Biotech CEOs to discuss funding challenges, navigating regulatory changes, and talent acquisition. Read more about our discussions and how we can support your journey: https://lnkd.in/gwNc4P48

#ICYMI our Chief Development Officer, Gilles Gallant, BPharm PhD FOPQ, joined industry leaders for Citeline Commercial’s roundtable at #BIO2024 exploring strategic practices, nuanced needs and key lessons for #biotech companies to consider when conducting #clinicaltrials.     Below, Dr. Gallant shares his insights on the value of diversifying clinical trials globally and maintaining a small, agile team to enhance operational efficacy and research outcomes. Check out additional highlights from the roundtable: https://bit.ly/4cmfzdw Biotechnology Innovation Organization

Exciting times in biotech! The first half of 2024 has seen near-record investment levels. Check out the EY German Biotechnology Report 2024 to see how we're part of this thriving sector.

There is Scope in Biotech! 💪Case Studies of Successful Biotechnologists - A Biotecnika Initiative 😇 👇 https://lnkd.in/garwDfEM #scope #biotechnology #casestudy #biotech #career #success